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Abstract  
Background: Selective serotonin reuptake inhibitor (SSRI) antidepressants have a 
delayed onset and commonly produce an incomplete therapeutic response.  The 
therapeutic actions of SSRIs are thought to depend on increased forebrain extracellular 
5-HT, following desensitization of somatodendritic 5-HT1A autoreceptors.  Here we 
determined whether concurrent glucocorticoid receptor (GR) blockade enhances these 
neurochemical responses to the SSRI, fluoxetine. 
Methods:  Male rats were treated (3, 7, or 14 days) with either fluoxetine (10 mg/kg i.p.) 
or vehicle once daily, in combination with either a GR antagonist (Org 34850 15 mg/kg 
s.c. or Org 34517 25 mg/kg s.c.) or vehicle twice daily.  Following treatment, 5-HT in the 
medial prefrontal cortex was measured by microdialysis.   
Results:  Chronic fluoxetine treatment (14 days) raised basal 5-HT and also attenuated 
the fall in 5-HT following acute systemic administration of fluoxetine (10 mg/kg i.p.) 
indicating desensitization of 5-HT1A autoreceptors.  Concurrent chronic dministration (14 
days) of Org 34850, or Org 34517, enhanced the fluoxetine-induced increase in basal 
5-HT.  Org 34850 also hastened the 5-HT1A autoreceptor desensitization induced by 
chronic fluoxetine treatment.  Org 34850 alone (14 days) failed to alter basal 5-HT or 
5-HT1A autoreceptor desensitization.  
Conclusion:  Antidepressant response is proposed to depend on 5-HT1A autoreceptor 
desensitization and elevation of forebrain 5-HT.  These data suggest adjunctive GR 
antagonists may both hasten and enhance antidepressant responses to SSRIs. 
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Introduction 
The goal of antidepressant therapy is rapid and complete relief of depressive symptoms in 
all patients.  However, the clinical profile of established antidepressant drugs is far from 
optimal: A delay in onset of therapeutic response (1) and partial responding in many 
patients (2) are two particular problems. 
 When administered chronically, the majority of effective antidepressants elevate 
extracellular 5-HT levels in the forebrain (3-5).  The finding that depletion of the 5-HT 
precursor tryptophan both reduces the SSRI-induced elevation of 5-HT in the rat 
forebrain (6) and leads to a rapid return of depressive symptoms in SSRI-treated patients 
(7), suggests that this common action is crucial for antidepressant efficacy.   
 In recent years, preclinical studies of the autoregulatory control of 5-HT 
neurotransmission have provided a plausible explanation for the delay in antidepressant 
onset.  Thus, the acute administration of selective serotonin reuptake inhibitors (SSRIs) 
elevates 5-HT in the dorsal raphe nucleus (DRN): the site of the somata of ascending 
5-HT neurones (8-10).  This increase in 5-HT activates inhibitory somatodendritic 
5-HT1A autoreceptors, resulting in a decrease in 5-HT release in the forebrain (11, 12).  
The decrease in release means that, although terminal 5-HT reuptake is inhibited, the 
SSRI is unable to elevate forebrain extracellular 5-HT.  However, chronic SSRI treatment 
desensitizes the inhibitory somatodendritic 5-HT1A autoreceptors (13-16), allowing DRN 
5-HT neuronal firing and 5-HT release to be restored and, with terminal reuptake 
inhibited, forebrain extracellular 5-HT increases (15, 17, 18).  The hypothesis that the 
delay in therapeutic onset of SSRIs reflects the time taken for DRN 5-HT1A receptors to 
desensitize has gained general acceptance, and treatments which aim to block 5-HT1A 
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autoreceptors or hasten their desensitization, in addition to providing 5-HT uptake 
blockade, are in development (19-23). 
 The problem of incomplete therapeutic response has received less attention 
and remains puzzling.  However, one possible explanation is that in some patients the 
neurochemical response is of insufficient magnitude to elicit a full antidepressant 
response.  Thus, in these patients there may be factors which reduce the ability of the 
antidepressant to elevate forebrain 5-HT.   
 In patients with depression, dysregulation of the hypothalamo-pituitary-
adrenal (HPA) axis is common (24, 25).  Circulating glucocorticoids influence several 
aspects of 5-HT neurotransmission including 5-HT1A autoreceptor function (26-29).  
Thus, we reasoned that the elevation of nadir cortisol levels seen in depressed patients 
(30, 31) may influence the neurochemical response and, hence, the antidepressant 
response to SSRIs.  In support of this we showed that flattening the glucocorticoid 
rhythm in the rat reduces the ability of an SSRI to elevate forebrain 5-HT levels (5).  
Furthermore, a recent clinical study in depressed patients showed that HPA axis 
dysfunction was associated with reduced SSRI efficacy (32).  In a further clinical study 
concurrent treatment with metyrapone (a steroid hormone synthesis inhibitor) increased 
both speed of onset and the response rate to a serotonergic antidepressant (33).  
Interestingly, the effect of metyrapone was independent of basal cortisol levels, indicating 
that antiglucocorticoid therapy may enhance antidepressant efficacy even in patients 
without overt HPA axis dysfunction. 
 The actions of glucocorticoid hormones in the brain are mediated in part by 
glucocorticoid receptors (GRs) (for review see 34).  In the present preclinical study we 
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sought to determine whether concurrent blockade of GRs, using GR antagonists Org 
34850 and Org 34517, would influence the neurochemical responses to an SSRI.  Our 
two primary outcome measures were the elevation of extracellular 5-HT in the prefrontal 
cortex (PFC) and the SSRI-induced desensitization of somatodendritic 5-HT1A 
autoreceptors.  In three sequential in vivo microdialysis experiments we determined: i) the 
time course of the emergence of neurochemical effects following combined Org 34850 
and fluoxetine treatment compared to fluoxetine alone, ii) whether Org 34850 alone had 
any effect, and iii) whether a second GR antagonist Org 34517 replicated the effects of 
Org 34850.  Some of these data have been presented as abstracts to the British 
Association for Psychopharmacology and European College for 
Neuropsychopharmacology. 
 
Methods and materials 
 
Animals 
All procedures were carried out in accordance with the UK Animals (Scientific 
Procedures) Act, 1986.  Adult male Hooded Lister rats (Charles River UK) were group 
housed in controlled environmental conditions on a 12 h light/dark cycle (lights on 7:00) 
with food and water available ad libitum.   
 
Chronic treatments  
The study comprised three separate experiments (see below).  For all three experiments 
the treatment protocol was as follows:- 
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the GR antagonists Org 34850 (15 mg/kg s.c.) or Org 34517 (25 mg/kg s.c.), or the 
vehicle (30% DMSO/70% PEG) were administered twice daily (7:00-8:00 and 18:00-
19:00).  Fluoxetine (10 mg/kg i.p.), or its vehicle (sterile water), was administered once 
daily (7:00-8:00).  All injections were given at a volume of 1 ml/kg.  Groups comprised 
8-12 animals. 
 
Experiment 1 
The time course of emergence of neurochemical effects in animals undergoing combined 
treatment with Org 34850 and fluoxetine was compared to that in animals treated with 
fluoxetine alone.  Paired groups of animals received Org 34850 and fluoxetine (Org 
34850/fluoxetine) or vehicle and fluoxetine (vehicle/fluoxetine) for 3, 7 or 14 days.  
Comparisons were also made with an untreated (control) group. 
 
Experiment 2  
This experiment examined whether Org 34850 alone had any effect on the neurochemical 
outcome measures independent of an interaction with fluoxetine.  A two-by-two design 
was used in which groups of animals were treated for 14 days with vehicle/vehicle, Org 
34850/vehicle, vehicle/fluoxetine, or Org 34850/fluoxetine. 
 
Experiment 3 
This experiment tested whether a second GR antagonist Org 34517 would replicate the 
effects of Org 34850.  Groups of animals were treated for 14 days with vehicle/vehicle, 
vehicle/fluoxetine, Org 34850/fluoxetine, or Org 34517/fluoxetine. 
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Microdialysis. 
Following chronic treatment animals underwent in vivo microdialysis.  Between 8:00 and 
9:00 (»25 h following the last fluoxetine or vehicle injection) animals were anaesthetised 
with chloral hydrate (500 mg/kg i.p. plus supplementary doses as necessary).  A 
concentric dialysis probe (3.0-3.5 mm dialysing window of Hospal membrane) was 
stereotaxically implanted into the right PFC (coordinates: 3.2 mm anterior, 1.0 mm lateral 
to bregma and 4.6 mm ventral to the dura surface (35)).  The probe was perfused (2.3 
µl/min) with an artificial CSF (see 5).  Dialysate samples were collected over 20 min 
periods and assayed for 5-HT by high-pressure liquid chromatography (5).  Dialysate 
samples were taken for 180 min.  The aCSF was then switched to one containing 
fluoxetine (10 mM) which was perfused for a further 200 min.  In Experiments 1 and 2, 
fluoxetine (10 mg/kg) was injected i.p. 80 min following the switch of perfusion.  At the 
end of the experiments animals were killed and the adrenal glands were removed and 
weighed. 
 
Basal samples were used to assess the effect of treatments on extracellular 5-HT levels.  
Dialysate 5-HT following local infusion of fluoxetine allowed assessment of the effect of 
the treatments on 5-HT release.  Finally, the fall in 5-HT levels following systemic 
injection of fluoxetine was used as an index of the sensitivity of somatodendritic 5-HT1A 
autoreceptors.   
 
Data Analysis 
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For statistical analysis, the dialysis data were reduced to three measures:  
· ‘Basal’ dialysate 5-HT levels -average of samples 1-3,  
· Dialysate 5-HT levels following local application of fluoxetine - average of 
samples 7 and 8 (Experiments 1 and 2) or samples 12 and 13 (Experiment 3).  
[Note that although in Experiments 1 and 2, sample 8 was collected after the 
systemic administration of fluoxetine, previous experiments have shown that the 
effect of i.p. fluoxetine is slow in onset (5)].   
· The fall in 5-HT level following an acute systemic injection of fluoxetine (an 
index of 5-HT1A receptor sensitivity) - average of samples 7 and 8 minus the 
average of samples 12 and 13).   
 
Experiment 1: data were analysed using a two-way ANOVA with treatment (vehicle 
or Org 34850) and duration (3, 7 or 14 days) as between-subjects factors.  One-way 
ANOVA with a post-hoc (LSD) analysis was also used to analyse data within treatment 
groups.  Experiment 2: data were analysed by two-way ANOVA.  Experiment 3: data 
were analysed by two-way ANOVA as well as one-way ANOVA (fluoxetine treated 
groups only) with post-hoc LSD tests.  Individual planned comparisons were also made 
by t test.  Significance at the 95% level is reported. 
 
Results 
Animal health 
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Animals appeared healthy and maintained a normal increase in body weight throughout 
treatments.  The only noted effect was that animals treated with the GR antagonists for 14 
days exhibited a slight thickening of the skin around the injection sites.   
 
Experiment 1. 
To examine the time course of the emergence of neurochemical effects following Org 
34850 and fluoxetine treatment compared to fluoxetine alone, groups of animals were 
treated for 3, 7 or 14 days with Org 34850/fluoxetine or vehicle/fluoxetine or were 
untreated controls (indicated as 0 days).  Figure 1 shows the full microdialysis time 
course for this experiment.  
 
Basal 5-HT levels 
As shown in Figure 2, following treatment with vehicle/fluoxetine basal dialysate 5-HT 
levels rose slightly but not significantly (p>0.05, one-way ANOVA).  In comparison, 
following Org 34850/fluoxetine treatment there was a marked and significant elevation in 
basal 5-HT levels (F3,33=4.6 p=0.009, one-way ANOVA).  This elevation was greater 
with increasing treatment duration and was significant at both 7 and 14 days (p=0.021 
and p=0.001, respectively, compared to the untreated controls).  A two-way ANOVA 
revealed a main effect of Org 34850 which was approaching significance (F1,49=4.0; 
p=0.051) but no main effect of duration and no significant duration x Org 34850 
interaction.   
 
5-HT release 
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Changing the perfusion to one containing fluoxetine (10 μM) markedly increased 
dialysate 5-HT (Figure 1).  Dialysate 5-HT levels after 60-80 min of local fluoxetine 
perfusion did not differ between groups (one-way and two-way ANOVA).   
 
5-HT1A autoreceptor sensitivity.  
The time-course of the response to acute systemic administration of fluoxetine is shown 
in Figure 1 and the response expressed as ‘change in 5-HT levels’ is shown in Figure 3.  
In the control group, systemic fluoxetine (10 mg/kg i.p.) caused a large fall in dialysate 
5-HT levels over the following 120 min.  In the vehicle/fluoxetine groups this response 
was attenuated.  Although the attenuation was not significant by one-way ANOVA across 
the 0, 3, 7 and 14 days groups (p=0.098), direct comparison by t test between the control 
and 14 day fluoxetine groups was statistically significant (p=0.016).   
 In the Org 34850/ fluoxetine groups there was a highly significant attenuation of 
the response to systemic fluoxetine (F3,33=8.8; p<0.0001, one-way ANOVA).  The 
attenuation was both earlier in onset and of greater magnitude than in the 
vehicle/fluoxetine groups.  The response was significantly different from the control 
group by 3 days (p=0.01), as well as at 7 (p<0.0001) and 14 days (p<0.0001, post-hoc 
LSD) (Figure 3).  A two-way ANOVA revealed a significant effect of Org 34850 
(F1,49=4.7; p=0.034), but no significant main effect of duration and no duration x Org 
34850 interaction.   
 
Adrenal weights. 
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The (combined) weights (in mg) of the adrenal glands were:- 57.7 ± 2.2 in the controls; 
67.0 ± 2.5, 60.9 ± 5.6, and 66.4 ± 1.4 in the vehicle/fluoxetine groups treated for 3, 7 and 
14 days respectively; and 62.4 ± 2.5, 77.1 ± 2.4, and 76.1 ± 4.6 in the Org 
34850/fluoxetine groups treated for 3, 7 and 14 days, respectively.  Vehicle/fluoxetine 
treatment had no effect on adrenal weight (p>0.05, one-way ANOVA).  In contrast, Org 
34850/fluoxetine treatment significantly increased adrenal weight (one-way ANOVA 
F6,57=5.9; p=0.0001; 7 days: p<0.0001, 14 days: p<0.0001, post-hoc LSD).  Two-way 
ANOVA showed a significant main effect of Org 34850 (F1,49=7.3; p=0.009) as well as 
an Org 34850 x duration interaction (F2,49=5.8; p=0.005).   
 
Experiment 2.  
The objective of this experiment was to determine whether Org 34850 alone could alter 
the neurochemical outcome measures independent of an interaction with fluoxetine.  On 
the basis of data from Experiment 1, we chose a fixed 14 day treatment period.  Animals 
were treated for 14 days with vehicle/vehicle, vehicle/fluoxetine, Org 34850/vehicle, or 
Org 34850/fluoxetine.  Figure 4 shows the full microdialysis time course. 
 
Basal 5-HT levels 
Basal 5-HT levels for the four groups are shown in Figure 5.  Chronic fluoxetine caused a 
highly significant elevation of basal 5-HT as reflected in a significant main effect in a 
two-way ANOVA (F1,30=44.4; p=0.0001).  There was no significant main effect of Org 
34850 and, whilst basal 5-HT levels were highest in the Org 34850/fluoxetine group, the 
Org 34850 x fluoxetine interaction was not significant (two-way ANOVA).  Direct 
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comparisons between groups showed no difference between the vehicle/vehicle and Org 
34850/vehicle, however, basal 5-HT was significantly higher in the Org 34850/fluoxetine 
group than the vehicle/fluoxetine group (t-test, p=0.046).   
 
5-HT release 
Local perfusion of fluoxetine (10 μM) markedly increased dialysate 5-HT levels (Figure 
4).  However, 60-80 min following local application of fluoxetine, dialysate 5-HT levels 
did not differ between groups.  Two-way ANOVA confirmed no significant effect of 
either treatment and no significant interaction between treatments.  
 
5-HT1A autoreceptor sensitivity 
Following systemic administration of fluoxetine, dialysate 5-HT levels fell (Figure 4).  
This response to fluoxetine injection was attenuated by fluoxetine (two-way ANOVA: 
significant main effect of fluoxetine (F1,30=31.4; p<0.001)) but there was no effect of Org 
34850 and no significant fluoxetine x Org 34850 interaction (Figure 6).  Direct 
comparisons between Org 34850/vehicle and vehicle/vehicle and between Org 
34850/fluoxetine and vehicle/fluoxetine groups by t test also showed no significant 
effect. 
 
Adrenal weight 
Adrenal weights (mg) were: vehicle/vehicle: 56.7 ± 1.7, vehicle/fluoxetine: 61.0 ± 3.4, 
Org 34850/vehicle: 68.3 ± 1.8, and Org 34850/fluoxetine 71.7 ± 1.8.  Statistical analysis 
revealed that whilst fluoxetine was without effect Org 34850 increased adrenal weight 
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(two-way ANOVA: significant main effect of Org 34850 (F1,30=24.2, p=0.0001).  There 
was no significant Org 34850 x fluoxetine interaction. 
 
Experiment 3 
In Experiment 3 we aimed to test whether the ability of Org 34850 to augment the 
fluoxetine-induced elevation of basal 5-HT observed in Experiments 1 and 2, could be 
replicated by a second GR antagonist Org 34517.  We also examined the response to 
local fluoxetine perfusion over an extended time period to confirm a lack of effect on 
5-HT release.  Groups of animals were treated for 14 days with vehicle/vehicle, 
vehicle/fluoxetine, Org 34850/fluoxetine, or Org 34517/fluoxetine.  Figure 7 shows the 
full microdialysis time course for this experiment. 
 
Basal 5-HT levels 
Basal 5-HT levels for the four groups are shown in Figure 8.  Chronic fluoxetine elevated 
basal 5-HT as revealed by a significant main effect of fluoxetine in a two-way ANOVA 
(F1,36=7.5; p=0.01).  However, there was also a significant main effect of GR antagonist 
(F2,36=4.7; p=0.016, two-way ANOVA).  Further analysis of the fluoxetine treated groups 
showed that both Org 34850 and Org 34517 enhanced the effect of fluoxetine compared 
to vehicle/fluoxetine treatment (F2,27=4.2, p=0.027, one-way ANOVA, Org 
34850/fluoxetine p=0.013, Org 34517/fluoxetine p=0.043 post-hoc LSD)  
 
5-HT release 
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As shown in figure 7, local fluoxetine perfusion (10 μM) markedly increased dialysate 
5-HT.  Mean dialysate 5-HT levels 160-180 min following local application of fluoxetine 
did not differ between groups.  Thus, two-way ANOVA showed no effect of fluoxetine or 
GR antagonist and one-way ANOVA (in fluoxetine treated groups) confirmed no 
significant effect of either Org 34850 or Org 34517 on 5-HT release compared to vehicle. 
 
Adrenal weights 
Adrenal weights (mg) were: vehicle/vehicle: 63.7 ± 2.7; vehicle/fluoxetine: 62.2 ± 1.1; 
Org 34850/vehicle: 80.3 ± 2.5; Org 34517/fluoxetine: 78.2 ± 3.5.  Two-way ANOVA 
revealed no significant effect of fluoxetine but a highly significant main effect of GR 
antagonist (F3,45=11.7; p=0.0001).  One-way ANOVA (F4,45=10.8, p<0.0001) with post-
hoc LSD showed that both Org 34850 (p<0.0001) and Org 34517 (p=0.0001) 
significantly increased adrenal weight compared to vehicle. 
 
Discussion 
The present study examined whether concurrent GR blockade influences the ability of 
chronic SSRI treatment to elevate extracellular 5-HT levels in the forebrain and 
desensitize 5-HT1A autoreceptors.  Org 34850 and Org 34517 both enhanced the effect of 
fluoxetine on basal 5-HT levels in the PFC.  Org 34850 hastened the fluoxetine-induced 
desensitization of 5-HT1A autoreceptors.  Org 34850 alone affected neither basal 5-HT 
levels nor the sensitivity of 5-HT1A autoreceptors, demonstrating that Org 34850 has a 
synergistic effect with the SSRI.  Both Org 34850 and Org 34517 have high affinity for 
GRs and show more than 300-fold selectivity for GRs versus mineralocorticoid receptors 
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(MRs) (Org 34850: pEC50 GR 8.0 and MR <5, Org 34517: pEC50 GR 7.7, MR <5 –
unpublished data from Organon Laboratories Ltd).  Thus, the present data indicate that 
GR antagonists may have adjunctive therapeutic benefit in enhancing the action of SSRIs. 
 
Fluoxetine-induced elevation of basal forebrain extracellular 5-HT is augmented by GR 
antagonists 
Chronic treatment with fluoxetine alone increased basal 5-HT in the PFC.  Although this 
effect was not statistically significant in Experiment 1, in Experiments 2 and 3 the 
elevation of 5-HT by fluoxetine was highly significant.  This finding of raised basal 
extracellular 5-HT many hours following the final dose of a chronic treatment with 
fluoxetine is consistent with our own and others’ data (5, 9, 36).  As the half-life of 
fluoxetine in the rat is 7-8 h (37), it is likely that reuptake blockade would be low when 
measurements were made.  Hence, it seems likely that the elevation of basal 5-HT results 
from a down-regulation of the 5-HT transporter (38-41). 
 Chronic treatment with a GR antagonist alone had no effect on basal extracellular 
5-HT in the PFC.  However, concurrent administration of the GR antagonist Org 34850 
enhanced the effect of fluoxetine on basal 5-HT levels, approximately doubling the effect 
of 14 days fluoxetine treatment.  This effect was evident in all three experiments 
(although in Experiment 2 only a planned comparison by t test showed significance) and 
was reproduced by a second GR antagonist, Org 34517.  The affinity of the drugs for 
5-HT1A receptors is unknown however, it seems highly unlikely that the GR antagonists 
are simply blocking 5-HT1A receptors since chronic Org 34850 failed to block the 
response to acute systemic administration of fluoxetine (Experiment 2).  We conclude 
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that GR antagonism represents a novel mechanism by which SSRI efficacy may be 
modulated. 
 We also measured extracellular 5-HT during local perfusion of fluoxetine.  As 
extracellular, and hence dialysate, levels of 5-HT are influenced primarily by the 
opposing processes of release and reuptake, measurements made in the presence of local 
reuptake blockade can be used as an index of release (11).  We found no significant 
effects of any of the treatments on 5-HT levels during local fluoxetine, indicating that 
none of the treatments influence the terminal 5-HT release. 
 
Fluoxetine-induced desensitization of 5-HT1A autoreceptors is hastened by a GR 
antagonist.  
It is established that when local terminal reuptake is inhibited, systemic administration of 
SSRIs decreases dialysate 5-HT in terminal regions (11, 12, 42, 43, 44).  This response is 
markedly attenuated by 5-HT1A receptor antagonists administered both systemically (11, 
12, 42, 43) and locally into the DRN (44).  The fall in dialysate 5-HT is thought to reflect 
the SSRI-induced inhibition of 5-HT neuronal firing and hence terminal release.  
Evidence from electrophysiological and microdialysis studies indicates that the effects of 
systemic SSRIs on 5-HT firing and release are mediated by somatodendritic 5-HT1A 
receptors and are not contributed to by postsynaptic feedback loops (45, 46).  These data 
indicate that the decrease in dialysate 5-HT following systemic administration of 
fluoxetine is principally mediated by somatodendritic 5-HT1A receptors.  Here we used 
the magnitude of the fall as an index of 5-HT1A autoreceptor sensitivity.  In Experiment 2 
after 14 days fluoxetine treatment the 5-HT1A autoreceptor-mediated response was 
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markedly desensitized consistent with previous reports (5, 15, 16).  In Experiment 1 the 
desensitization induced by fluoxetine (alone) was less consistent and was not statistically 
significant by ANOVA.  However, importantly, concurrent treatment with Org 34850 
hastened the time-course of the desensitization in Experiment 1, such that a significant 
effect was observed after just 3 days of the combined treatment.  In Experiment 2, the 
near complete desensitization with fluoxetine alone produced a floor effect and Org 
34850 had no additional effect over that of fluoxetine.  In contrast to our observation, Le 
Poul and colleagues (47) showed no effect of another GR antagonist (RU 38486) on 
5-HT1A receptor desensitization induced by fluoxetine.  It is not clear what factors 
underlie this discrepancy but they may include partial GR agonist effects of RU 38486 
(48) and/or differences in treatment dose and duration or measures made.  
 On acute administration SSRIs, like fluoxetine, have limited effects on 
extracellular 5-HT in the forebrain (12, 49) probably because they indirectly activate 
5-HT1A autoreceptors and, thereby, reduce terminal 5-HT release.  Removal of this 
inhibitory feedback allows the SSRI to exert its full effect on forebrain extracellular 5-HT 
levels.  Hence, the earlier desensitization of 5-HT1A autoreceptors in Org 
34850/fluoxetine-treated animals may (at least partly) underlie the earlier increase in 
extracellular 5-HT observed in this group (but see below).   
 
GR antagonists increased adrenal gland weight.  
Both Org 34850 and Org 34517 increased adrenal gland weight.  Here. the use of 
anaesthetic precluded determination of basal corticosterone levels, however, in a separate 
experiment, we found that while fluoxetine alone had no effect on morning (nadir) 
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corticosterone levels, Org 34850 moderately increased levels and the combination of Org 
34850/ fluoxetine had a greater effect (manuscript in preparation).  Bachmann et al. (50) 
also found that the GR antagonists increased adrenal weight but neither Org 34850 nor 
Org 34517 elevated morning corticosterone levels.  Raised corticosterone has been shown 
to attenuate 5-HT1A receptor sensitivity (26, 29).  However, our finding that Org 34850 
alone failed to alter 5-HT1A receptor sensitivity suggests that the 5-HT1A autoreceptor 
desensitization is not mediated by increased corticosterone.  
 
Putative mechanisms underlying the interactions between GR antagonists and SSRIs. 
Although we found a hastening of 5-HT1A autoreceptor desensitization, our finding that 
the effect of Org 34850/fluoxetine on basal 5-HT levels after 14 days occurred in the 
absence of any augmentation of this 5-HT1A autoreceptor desensitization suggests a 
second independent interaction between the two treatments.  Thus, two distinct processes 
appear to be affected by a synergistic interaction between fluoxetine and GR antagonists.  
As 5-HT release was not altered, the most likely mechanism underlying elevated basal 
5-HT levels is a synergistic effect of fluoxetine and the GR antagonist on 5-HT reuptake.   
The present study did not address the mechanisms underlying the synergistic 
interactions between GR antagonists and fluoxetine.  However, the possibility of a 
pharmacokinetic interaction raising brain levels of fluoxetine seems unlikely, since the 
two drugs are chemically dissimilar and are metabolised by different routes (51; Organon 
unpublished data).  More likely, the blockade of GRs - which are expressed in 5-HT 
neurones in the DRN (52, 53) - could influence receptor and/or transporter proteins 
within 5-HT neurones.  Although Org 34850 had no effect on its own suggesting that 
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normal diurnal levels of glucocorticoids do not exert a GR-mediated tonic regulation on 
5-HT neurones, the synergy might be explained by the fact that SSRIs elevate 
corticosterone (54).  Thus the combination of the GR antagonist and SSRI may block the 
effect of this elevated corticosterone.   
 
Behavioural effects of GR blockade. 
Although the potential effects of the Org 34850 and Org 34517 on behaviour were not 
examined here, it is of note that behaviours relevant to anxiety and depression are 
reported to be influenced glucocorticoid receptor function.  Thus, chronic GR antagonists 
reportedly reverse depression-associated behaviours induced by chronic mild stress in 
rats (55) although anxiety-like behaviour on the elevated plus maze is unaffected (56).  
GR knock-out mice have also been reported to show reduced anxiety behaviour in several 
tests (57, 58).  These data suggest that reduced GR activation, like antidepressants, might 
promote ‘behavioural resilience’.  Clearly, studies on the behavioural effects of Org 
34850 and Org 34517 both alone and in combination with SSRIs are warranted. 
 
Clinical implications. 
Evidence indicates that an increase in 5-HT neurotransmission is critical for 
antidepressant efficacy (7).  However, this increase is manifest only after several weeks at 
a time when 5-HT1A autoreceptors have become desensitized (1).  Our data, showing that 
GR antagonists can hasten the SSRI-induced desensitization of 5-HT1A autoreceptors, 
suggest that concurrent GR antagonist treatment may hasten the onset of clinical 
antidepressant effects of SSRIs.  The clinical observation of partial response to SSRIs 
Johnson DA 
 - 20 - 
may reflect an inadequate neurochemical response to the antidepressant in some patients.  
Our finding that GR antagonists can augment the magnitude of the effect of the SSRI on 
extracellular 5-HT after longer treatment duration suggests an adjunctive treatment 
combining GR antagonists and SSRIs might augment the clinical response in patients 
with residual depression.  Finally, since our experiments were conducted in animals with 
normal HPA axis, our findings suggest that GR antagonist augmentation of SSRI 
treatment may be beneficial even in patients without HPA dysfunction.  
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Figure 1. Experiment 1:  Time course of changes in 5-HT levels for the untreated control 
group and the three vehicle/fluoxetine treatment groups (A) and the three Org 
34850/fluoxetine treatment groups (B).  Horizontal bar indicates switching of the 
perfusion medium to one containing fluoxetine (10 μM).  The arrow represents a single 
systemic injection of fluoxetine (10 mg/kg i.p.).  Data are mean dialysate 5-HT content.  
Error bars omitted for clarity.  
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Figure 2. Experiment 1:  Basal 5-HT levels (average of samples 1-3) in the three 
Vehicle/fluoxetine and Org 34850/fluoxetine treatment groups and the untreated control 
group.  Data are mean + SEM. *p<0.05, one-way ANOVA and post-hoc LSD tests, see 
text for further statistical analysis. 
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Figure 3. Experiment 1: Responses to a systemic injection of fluoxetine (10 mg/kg i.p.) 
in the three Vehicle/fluoxetine and Org 34850/fluoxetine treatment groups and the 
untreated control group.  Data represent the fall in 5-HT levels following fluoxetine 
injection (average of samples 7 and 8 minus the average of samples 12 and 13).  *p<0.05, 
one-way ANOVA and post-hoc LSD tests, see text for further statistical analysis. 
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Figure 4. Experiment 2: Time course of changes in 5-HT levels for the vehicle/vehicle, 
Org 34850/vehicle, vehicle/fluoxetine and Org 34850/fluoxetine treatment groups.  
Horizontal bar indicates switching of the perfusion medium to one containing fluoxetine 
(10 μM).  The arrow represents a single systemic injection of fluoxetine (10 mg/kg i.p.).  
Data are mean dialysate 5-HT values.  Error bars omitted for clarity.  
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Figure 5. Experiment 2: Basal 5-HT levels (average of samples 1-3) in the 
vehicle/vehicle, vehicle/fluoxetine, Org 34850/vehicle and Org 34850/fluoxetine groups 
after 14 days of treatment.  Data represent mean + SEM *p<0.05, t-test. 
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Figure 6. Experiment 2:  Response to a systemic injection of fluoxetine (10 mg/kg i.p) in 
the vehicle/vehicle, vehicle/fluoxetine, Org 34850/vehicle and Org 34850/fluoxetine 
treatment groups.  Data represent the fall in 5-HT (average of samples 7 and 8 minus the 
average of samples 12 and 13) following injection of fluoxetine. See text for full 
statistical analysis. 
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Figure 7. Experiment 3: Time course of changes in 5-HT levels for the vehicle/vehicle, 
vehicle/fluoxetine, Org 34850/fluoxetine and Org 34517/fluoxetine treatment groups.  
Horizontal bar indicates switching of the perfusion medium to one containing fluoxetine 
(10 μM).  Data are mean dialysate 5-HT. Error bars omitted for clarity.  
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Figure 8. Experiment 3: Basal 5-HT levels in the vehicle, vehicle/fluoxetine, Org 
34850/fluoxetine and Org 34517/fluoxetine groups after 14 days of treatment.  Data 
represent mean + SEM calculated from dialysate samples 1-3.  (*p<0.05, one-way 
ANOVA and post-hoc LSD tests) see text for further statistical analysis. 
 
 
